Antitumor dibenzofluorene derivatives

Details Antitumor dibenzofluorene derivatives Antitumor dibenzofluorene derivatives

2000-08-08

2002-03-26

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S195000

Reexamination Certificate

active

06362200

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates to compounds having antitumor activity. The invention also relates to pharmaceutical compositions that contain one or more of those compounds, methods of using the compounds to inhibit tumor growth in mammals, and methods of preparing the compounds.
Many thousands of people are diagnosed with cancer each year, and although great advances have been made in cancer therapy, the existing treatments are not successful in many cases. Among the problems with existing therapies are (1) anticancer drugs administered to patients often have toxic effects on non-cancerous cells in the patient's body, (2) cancerous cells whose growth can be inhibited by certain drugs sometimes become resistant to those drugs, and (3) some cancers cannot be effectively treated with a single drug, and sometimes not even with a combination of different anticancer drugs. A long-standing need exists for new anticancer drugs that have one or more of the following characteristics: (1) ability to inhibit the growth of cancerous cells, (2) acceptable levels of toxicity to non-cancerous cells, (3) effectiveness against cancerous cells that are resistant to other drugs, and (4) a different mechanism of action than existing drugs, so that when the new drug is used in combination with an existing drug, the likelihood of the cancer cells developing cross-resistance is reduced.
SUMMARY OF THE INVENTION
The present invention concerns compounds having a formula selected from the group consisting of
or salts thereof. In the above formulas, at least one of R
1
-R
13
in formula (I) or at least one of R
1
-R
12
in formula (II) is —R
14
Z. R
14
is a substituted or unsubstituted amino or amido group preferably having from 1-12 carbon atoms. Z is a substituted or unsubstituted heterocyclic group preferably having from 1-12 carbon atoms. The remainder of R
1
-R
13
in formula (I) or R
1
-R
12
in formula (II) are independently selected from the group consisting of hydrogen, hydroxyl, halogen, nitro, substituted or unsubstituted amino or amido groups preferably having from 1-12 carbon atoms, and alkyl groups preferably having from 1-12 carbon atoms.
As mentioned above, salts of the compounds (I) and (II) are part of the present invention. Examples of suitable salts include but are not limited to the hydrochloride, iodide, and methane sulfonate salts.
In one embodiment of the invention where the compound has formula I, R
11
is —R
14
Z, and R
1
-R
10
and R
12
-R
13
are independently hydrogen, hydroxyl, halogen, nitro, substituted or unsubstituted amino or amido having from 1-12 carbon atoms, or alkyl having 1-12 carbon atoms
In another embodiment of the invention where the compound has formula II, R
11
is —R
14
Z, and R
1
-R
10
and R
12
are independently hydrogen, hydroxyl, halogen, nitro, substituted or unsubstituted amino or amido having from 1-12 carbon atoms, or alkyl having 1-12 carbon atoms.
R
14
preferably has the formula —NHR
15
—, where R
15
is a substituted or unsubstituted aliphatic group having from 2-6 carbon atoms. R
15
preferably is selected from the group consisting of —CO(CH
2
)
n
CO—, —(CH
2
)
m
—, and —CO(CH
2
)
q
CHCH(CH
2
)
r
CO—, where n, m, q, and r are independently a number from 0-6. In one preferred embodiment of the invention, n is from 1-4, m is from 2-6, q is from 0-2, and r is from 0-2. Z preferably is selected from the group consisting of piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, hydroxyethyl piperazinyl, aminoethyl piperazinyl, and aminomethyldihydroxy piperidinyl.
Another aspect of the present invention is pharmaceutical compositions that comprise a compound as described above and a pharmaceutically acceptable carrier. Yet another aspect of the present invention is a method of inhibiting the growth of tumor cells, in which a tumor-inhibitory amount of a compound as described above is administered to a mammal.
Another aspect of the present invention is a method of synthesizing a cyclic hydrocarbon and keto compound. The method comprises the step of reacting a cyclic hydrocarbon compound that comprises at least two rings with a metal bismuthate in the presence of an acid. The metal bismuthate can be for example an alkali metal bismuthate such as sodium bismuthate. As another example, it can be zinc bismuthate. In certain embodiments of this method, the acid can be an organic acid such as acetic acid or a mineral acid such as sulfuric acid. Optionally the reaction can take place in the presence of an organic solvent, such as acetone. The cyclic hydrocarbon reactant preferably comprises from 10-50 carbon atoms.
The compounds and compositions of the present invention are useful in cancer therapy, either by themselves or in combination with other antitumor chemotherapy or radiation therapy.


REFERENCES:
patent: 743137 (1966-09-01), None
Cherubim et al., “Synthesis and Biological Evaluation of Phenanthrene-Derived Carboxamides as Cytotoxic Agents,”Anti-Cancer Drug Design8:429-438 (1993).
Sami et al., “2-Substituted 1,2-Dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A New Class of Antitumor Agent,”J. Med. Chem.36:765-770 (1993).
Yu et al., “Phenothiazines as Lipid Peroxidation Inhibitors and Cytoprotective Agents,”J. Med. Chem.35:716-724 (1992).
Leon et al., “Modulation of the Antitumor Activity by Methyl Substitutions in the Series of 7H-Pyridocarbazole Monomers and Dimers,”J. Med. Chem.30:2074-2080 (1997).
Bair et al., “2-[Arylmethyl)Amino]-2-Methyl-1,3-Propanediol DNA Intercalators. An Examination of the Effects of Aromatic Ring Variation on Antitumor Activity and DNA Binding,”J. Med. Chem.34:1983-1990 (1991).
Nakanishi et al., “Studies of Piperidine Derivatives,”J. Med. Chem.13:644-648 (1970).
“Chrysene,”Polycyclic Aromatic Hydrocarbon Structure Index,No. 39, NIST Special Publication 922 (Aug. 18, 1998).
“7H-Benzo[hi]chrysene,”Polycyclic Aromatic Hydrocarbon Structure Index,No. 106, NIST Special Publication 922 (Aug. 18, 1998).
“Dibenzo[c,l]chrysene,”Polycyclic Aromatic Hydrocarbon Structure Index,No. 293, NIST Special Publication 922 (Aug. 18, 1998.
“Dibenzo[c,p]chrysene,”Polycyclic Aromatic Hydrocarbon Structure Index,No. 276, NIST Special Publication 922 (Aug. 18, 1998).
“Dibenzo[def,mno]chrysene,”Polycyclic Aromatic Hydrocarbon Structure Index,No. 121, NIST Special Publication 922 (Aug. 18, 1998).
Derwent Abstract, “Correlations Between Topological Resonance Energy of Methyl-Substituted benz[c]acridines, benzo[a]phenothiazines and chrysenes, and their carcinogenic or antitumor activities,” Kurihara et al., Anticancer Res., 16(5A), p. 2757-65 (Sep.-Oct. 1996).
Derwent Abstract, “Use of Precision-Cut Liver Slices to Evaluate Species Differences in 2-Acetylaminofluorene-induced unscheduled DNA Synthesis,” Lake et al.,Toxicol. Appl. Pharmacol.,138(2), p. 231-41 (Jun. 1996).
Derwent Abstract, “Absence of Mutagenicity of Benzo[c]Phenathridine Alkaloids in Somatic Cells of Drosophila Melanogaster: Comparison with 7,12-dimethylbenz[a] Anthracene and Chrysene,” Perez-Chiesa et al.,Mutat. Res.,298(4), p. 277-83 (Feb. 1993).
Derwent Abstract, “Characterization of Cytochrome P-450 2B6 in Human Liver Microsomes,” Mimura et al.,Drug Metab. Dispos.,21(6), p. 1048-56 (Nov.-Dec. 1993).
Derwent Abstract, “A Phase II Study of Crisnatol Mesylate in Patients with Ovarian Carcinoma,” Smalley et al.,Invest. New Drugs,10(2), p. 107-12 (Jul. 1992).
Derwent Abstract, “Microbial Production of a Crisnatol Metabolite,” Hufford et al.,Pharm. Res.,9(5), p. 623-5 (May 1992).
Derwent Abstract, “An Efficient Multiple-Exposure Analysis of the Toxicity of Crisnatol, a DNA Intercalator in Phase II Clinical Trials,” Zucker et al.,Invest. New Drugs,10(1), pp. 1-15 (Apr. 1992).
Derwent Abstract, “New Anticancer Agents,” Brown et al.,Cancer Chemother Biol. Response Modif.,12, p. 111-46 (1991).
Derwent Abstract, “Disposition, Metabolism, and Excretion of the Anticancer Agent Crisnaiol in the Rat,” Patel et al.,Drug Metab. Dispos.,19(2), 49

Affiliated with

Also associated with

Rating

Antitumor dibenzofluorene derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antitumor dibenzofluorene derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumor dibenzofluorene derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2847974